Sarepta Therapeutics (SRPT) Stock Analysis & Winston Score

Sarepta Therapeutics is a biotech company that makes medicines for rare genetic muscle diseases, mainly Duchenne muscular dystrophy (DMD). DMD is a severe condition that affects mostly young boys, causing progressive muscle weakness. Sarepta's main products include exon-skipping drugs like Exondys 51, Vyondys 53, and Amondys 45, as well as Elevidys, a gene therapy for DMD approved by the FDA in 2023. Sarepta earns money by selling these prescription drugs to patients, primarily in the United States, though it is expanding internationally through partnerships. With a market cap of about $1.7 billion and a gross margin above 60%, the company has pricing power in a niche where few competitors exist. However, its operating margin is slightly negative, meaning it still spends heavily on research. The biggest growth driver is broader adoption of Elevidys, its gene therapy, but the main risk is that insurers may limit coverage due to the drug's very high price tag.